The approval is based on findings from the CIRCUIT trial published in JAMA in October 2025.

Tandem Diabetes Care has announced that the U.S. Food and Drug Administration (FDA) has cleared Control-IQ+ automated insulin delivery (AID) technology for use in pregnancy complicated by ...

Abbott’s latest innovation, the FreeStyle Libre® 2 Plus sensor, is available for the first time for t:slim X2™ insulin pump users in the U.S. Tandem’s Control-IQ™ hybrid closed-loop technology now ...

Tandem Diabetes Care (Nasdaq:TNDM) today announced FDA clearance for its automated insulin delivery technology for use in ...

Tandem Diabetes Care, Inc.’s TNDM flagship t:slim X2 insulin pump with Control-IQ automated insulin delivery (AID) technology is now certified for use with Eli Lilly and Company’s LLY Lyumjev (insulin ...

The FDA cleared an automated insulin delivery system for use by pregnant women with type 1 diabetes, according to an industry ...

US FDA clears Tandem Diabetes Care’s Control-IQ+AID technology for use in pregnancy complicated type 1 diabetes mellitus: San Diego Wednesday, April 29, 2026, 16:00 Hrs [IST] Ta ...

MARKHAM, Ontario--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM) and Dexcom, Inc. today announced that following the recent authorization of sale by Health Canada, in-warranty t:slim X2™ ...

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced the launch of updated t:slim X2™ insulin pump ...

SAN DIEGO--(BUSINESS WIRE)-- Tandem Diabetes Care, Inc. (TNDM), a leading insulin delivery and diabetes technology company, today announced that its t:slim X2™ insulin pump with Control-IQ+ automated ...